Where Atara Biotherapeutics Stands With Analysts
Portfolio Pulse from Benzinga Insights
Atara Biotherapeutics (NASDAQ:ATRA) has been rated by 4 analysts over the past 3 months, with 1 bullish, 1 indifferent, and 2 bearish ratings. The average 12-month price target is $7.72, a decrease of 35.67% from the previous target of $12.00. The high target is $28.00 and the low is $0.50. Analyst ratings are important as they provide investors with insights into stock performance based on research and financial analysis.
November 10, 2023 | 4:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Atara Biotherapeutics has a mixed outlook from analysts with an average price target of $7.72, reflecting a significant decrease from the previous target. The stock may experience volatility due to these revised targets and analyst sentiment.
The average price target for Atara Biotherapeutics has been lowered, which could lead to negative investor sentiment in the short term. However, the presence of both bullish and bearish ratings indicates uncertainty and potential volatility, rather than a clear direction for the stock price.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100